ES2186811T3 - Derivados de feniltiazol con propiedades anti-virus herpes. - Google Patents

Derivados de feniltiazol con propiedades anti-virus herpes.

Info

Publication number
ES2186811T3
ES2186811T3 ES96945567T ES96945567T ES2186811T3 ES 2186811 T3 ES2186811 T3 ES 2186811T3 ES 96945567 T ES96945567 T ES 96945567T ES 96945567 T ES96945567 T ES 96945567T ES 2186811 T3 ES2186811 T3 ES 2186811T3
Authority
ES
Spain
Prior art keywords
herpes
derivatives
phenyltiazol
properties
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945567T
Other languages
English (en)
Inventor
James J Crute
Anne-Marie Fauche
Christopher A Grygon
Karl D Hargrave
Bruno Simoneau
Bounkham Thavonekham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Canada Ltd
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Canada Ltd
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Canada Ltd, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMA
Application granted granted Critical
Publication of ES2186811T3 publication Critical patent/ES2186811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A METODOS PARA INHIBIR LA REPLICACION DE HERPES Y PARA TRATAR INFECCIONES POR HERPES EN UN MAMIFERO MEDIANTE INHIBICION DEL COMPLEJO ENZIMATICO HELICASA-PRIMASA DEL HERPES. ESTA INVENCION TAMBIEN SE REFIERE A DERIVADOS TIAZOLILFENILO DE FORMULA (G) QUE INHIBEN EL COMPLEJO HELICASAPRIMASA DEL HERPES Y A COMPOSICIONES FARMACEUTICAS QUE INCLUYEN LOS DERIVADOS TIAZOLILFENILO, A METODOS PARA USAR Y METODOS PARA PRODUCIR LOS DERIVADOS TIAZOLILFENILO. EN LA FORMULA (G), R Y Z SON COMO SE DEFINE EN LA APLICACION EN LA QUE Z ES EL RASGO CARACTERISTICO.
ES96945567T 1995-12-29 1996-12-04 Derivados de feniltiazol con propiedades anti-virus herpes. Expired - Lifetime ES2186811T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US943395P 1995-12-29 1995-12-29
US2320996P 1996-08-02 1996-08-02

Publications (1)

Publication Number Publication Date
ES2186811T3 true ES2186811T3 (es) 2003-05-16

Family

ID=26679472

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945567T Expired - Lifetime ES2186811T3 (es) 1995-12-29 1996-12-04 Derivados de feniltiazol con propiedades anti-virus herpes.

Country Status (26)

Country Link
US (3) US6057451A (es)
EP (1) EP0871619B1 (es)
JP (1) JP4327249B2 (es)
KR (1) KR19990076964A (es)
AR (1) AR037060A1 (es)
AT (1) ATE227279T1 (es)
AU (1) AU1682897A (es)
BG (1) BG102583A (es)
BR (1) BR9612435A (es)
CA (1) CA2192433C (es)
CZ (1) CZ207298A3 (es)
DE (1) DE69624728T2 (es)
DK (1) DK0871619T3 (es)
EA (1) EA199800611A1 (es)
EE (1) EE9800154A (es)
ES (1) ES2186811T3 (es)
HU (1) HUP9902341A2 (es)
IL (1) IL124436A0 (es)
MX (1) MX9805291A (es)
NO (1) NO982950L (es)
NZ (1) NZ331104A (es)
PL (1) PL327582A1 (es)
PT (1) PT871619E (es)
SK (1) SK89398A3 (es)
TR (1) TR199801244T2 (es)
WO (1) WO1997024343A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
WO2000026197A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
CA2366607A1 (en) 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DE19927415A1 (de) * 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
CA2377771A1 (en) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
AU2000259734A1 (en) * 2000-06-15 2001-12-24 Gerald Kleymann Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
KR100453080B1 (ko) * 2000-08-21 2004-10-15 주식회사 태평양 신규 티오카르밤산 유도체 및 이를 함유하는 약제학적조성물
WO2002016319A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same
DE60133743T2 (de) 2000-08-21 2009-07-02 Pacific Corp. Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
EP1340750B8 (en) * 2000-11-10 2005-10-19 Astellas Pharma Inc. Amide derivatives
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
WO2003082826A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
WO2003095435A1 (fr) * 2002-05-09 2003-11-20 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amides
CA2503844A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
CA2514573A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
US20060229346A1 (en) * 2003-03-31 2006-10-12 Sucampo Ag Method for treating vascular hyperpermeable disease
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
KR20050039573A (ko) * 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US20070269420A1 (en) * 2003-11-24 2007-11-22 Chunduru Srinivas K Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases
EP2287194B1 (en) 2004-03-12 2016-10-26 Vasgene Therapeutics, Inc. Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
JP5011739B2 (ja) * 2005-02-03 2012-08-29 アステラス製薬株式会社 テトラヒドロ−２ｈ−チオピラン−４−カルボキサミド誘導体を含有する医薬組成物
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
SG159561A1 (en) * 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
CA2613354A1 (en) * 2005-06-24 2007-01-04 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2661863A1 (en) * 2006-08-30 2008-03-06 F. Hoffmann-La Roche Ag Inhibitors for glyt-1
WO2008154601A1 (en) * 2007-06-12 2008-12-18 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
WO2010047295A1 (ja) 2008-10-20 2010-04-29 アステラス製薬株式会社 帯状疱疹関連痛の予防又は治療薬
JP5583694B2 (ja) * 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するピロリジン化合物
US8822515B2 (en) 2009-10-16 2014-09-02 University Of Maryland, Baltimore County Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
WO2012113920A1 (en) 2011-02-24 2012-08-30 Katholieke Universiteit Leuven Arylsulfone derivatives with activity against human betaherpesviruses
KR101399484B1 (ko) * 2011-07-14 2014-05-29 한국화학연구원 허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
UY35772A (es) 2013-10-14 2015-05-29 Bayer Cropscience Ag Nuevos compuestos plaguicidas
JP6698083B2 (ja) * 2014-11-10 2020-05-27 エヴリース・バイオ, エルエルシーEvrys Bio, LLC 抗ｈｃｍｖの組成物及び方法
JP6749344B2 (ja) * 2015-02-13 2020-09-02 アジエンダ・オスペダリエラ・ウニベルシタリア・セネーゼ 治療剤としてのヒトヘリカーゼｄｄｘ３阻害剤
PE20181804A1 (es) 2016-04-06 2018-11-19 Innovative Molecules Gmbh Derivados de aminotiazol utiles como agentes antiviricos
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
AR113344A1 (es) 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
EP3818053B1 (en) 2018-07-05 2023-03-29 Sanford Burnham Prebys Medical Discovery Institute Fused ring compound having urea structure
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
WO2020127685A1 (en) * 2018-12-19 2020-06-25 Leo Pharma A/S Amino-acid anilides as small molecule modulators of il-17
CA3155287A1 (en) 2019-09-26 2021-04-01 Novartis Ag Antiviral pyrazolopyridinone compounds
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629247A (en) * 1969-06-06 1971-12-21 Pfizer Thiazoline and 5 6-dihydro-4h-1 3-thiazine antiviral agents
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH075579B2 (ja) * 1986-09-01 1995-01-25 吉富製薬株式会社 アミノチアゾ−ル化合物
MX174210B (es) * 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
HU207310B (en) * 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives
FR2656610B1 (fr) * 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
WO1992012635A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression of viral genes and other genes
GB9125970D0 (en) * 1991-12-06 1992-02-05 Fujisawa Pharmaceutical Co New compounds
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
GB2276164A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
AU701776B2 (en) * 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
AU3289299A (en) * 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents

Also Published As

Publication number Publication date
AU1682897A (en) 1997-07-28
NO982950D0 (no) 1998-06-25
PT871619E (pt) 2003-03-31
EA199800611A1 (ru) 1999-04-29
HUP9902341A2 (hu) 1999-10-28
IL124436A0 (en) 1998-12-06
US6458959B1 (en) 2002-10-01
PL327582A1 (en) 1998-12-21
NZ331104A (en) 2000-03-27
BR9612435A (pt) 1999-07-13
TR199801244T2 (xx) 1998-12-21
WO1997024343A1 (en) 1997-07-10
JP2000502702A (ja) 2000-03-07
NO982950L (no) 1998-06-25
US6348477B1 (en) 2002-02-19
ATE227279T1 (de) 2002-11-15
EE9800154A (et) 1998-12-15
KR19990076964A (ko) 1999-10-25
BG102583A (en) 1999-06-30
CZ207298A3 (cs) 1998-11-11
CA2192433A1 (en) 1997-06-30
EP0871619A1 (en) 1998-10-21
DK0871619T3 (da) 2003-03-03
EP0871619B1 (en) 2002-11-06
JP4327249B2 (ja) 2009-09-09
SK89398A3 (en) 1998-11-04
AR037060A1 (es) 2004-10-20
CA2192433C (en) 2008-01-08
DE69624728D1 (de) 2002-12-12
DE69624728T2 (de) 2003-07-10
US6057451A (en) 2000-05-02
MX9805291A (es) 1998-10-31

Similar Documents

Publication Publication Date Title
ES2186811T3 (es) Derivados de feniltiazol con propiedades anti-virus herpes.
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
BR0213129A (pt) Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
MX9304359A (es) Derivados de rapamicina.
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
UY25330A1 (es) Nuevos macrólidos
ES2183937T3 (es) Inhibidores de la adhesion celular.
GT200000198A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
GT200600398A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
UY25780A1 (es) Nuevos antibióticos macrólidos
ES2185760T3 (es) Composicion farmaceutica para el tratamiento del herpes.
MX9304361A (es) Derivados de rapamicina.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.